Version history

1 version on record. Newest first; the live version sits at the top with a live indicator.

  1. Live
    4/16/2026, 1:56:01 PM
    Content snapshot
    {
      "session_id": "sess_SDA-2026-04-16-gap-debate-20260410-113104-a13caf2e_20260416-135601",
      "round_number": 4,
      "agent_persona": "persona-synthesizer",
      "agent_backend": "minimax/MiniMax-M2.7",
      "action": "synthesize",
      "content": "\n\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"title\": \"Microglial Cholesterol Accumulation Driving NLRP3 Inflammasome Activation\",\n      \"mechanism\": \"APOE4 impairs microglial ABCA1/ABCG1-mediated cholesterol efflux, causing intracellular cholesterol accumulation that primes NLRP3 inflammasome assembly and IL-1β/IL-18 release.\",\n      \"target_gene\": \"ABCA1, ABCG1\",\n      \"confidence_score\": 0.7,\n      \"novelty_score\": 0.5,\n      \"feasibility_score\": 0.6,\n      \"impact_score\": 0.8,\n      \"composite_score\": 0.68,\n      \"testable_prediction\": \"APOE4 microglia show increased intracellular cholesterol and elevated NLRP3/ASC speck formation compared to APOE3, blocked by ABCA1 agonists.\",\n      \"skeptic_concern\": \"Whether this inflammatory priming is primary or secondary to neuronal damage in AD progression.\"\n    },\n    {\n      \"rank\": 2,\n      \"title\": \"SREBP2 Cleavage Dysregulation by Unlipidated APOE4\",\n      \"mechanism\": \"APOE4's reduced lipid-binding affinity fails to retain SCAP-SREBP2 complexes in the ER, causing constitutive SREBP2 nuclear translocation and HMGCR/FDFT1 activation.\",\n      \"target_gene\": \"SREBF2, HMGCR\",\n      \"confidence_score\": 0.45,\n      \"novelty_score\": 0.6,\n      \"feasibility_score\": 0.5,\n      \"impact_score\": 0.65,\n      \"composite_score\": 0.52,\n      \"testable_prediction\": \"APOE4 astrocytes show increased nuclear SREBP2 and HMGCR expression independent of sterol levels, abolished by APOE4 lipid reconstitution.\",\n      \"skeptic_concern\": \"Canonical SREBP2 pathway operates via SCAP-Insig sterol sensing with no established role for secreted apolipoproteins; mechanistic link is speculative.\"\n    },\n    {\n      \"rank\": 3,\n      \"title\": \"Compensatory Cholesterol Synthesis to Counteract Efflux Deficit\",\n      \"mechanism\": \"APOE4 carriers show elevated cholesterol synthesis as an adaptive response to impaired lipid binding and efflux capacity, rather than a primary pathogenic mechanism.\",\n      \"target_gene\": \"HMGCR, FDFT1\",\n      \"confidence_score\": 0.4,\n      \"novelty_score\": 0.55,\n      \"feasibility_score\": 0.45,\n      \"impact_score\": 0.6,\n      \"composite_score\": 0.48,\n      \"testable_prediction\": \"APOE4 iPSC-derived neurons maintain normal membrane cholesterol despite elevated synthesis, indicating compensatory equilibrium disrupted only under additional stress.\",\n      \"skeptic_concern\": \"If truly compensatory, APOE4 carriers would not show net lipid deficits in steady-state conditions, challenging the therapeutic rationale for lipid-based interventions.\"\n    }\n  ],\n  \"consensus_points\": [\n    \"APOE4 carriers consistently show enhanced cholesterol synthesis markers across AD cohorts\",\n    \"APOE4 impairs ABCA1/ABCG1-dependent lipid efflux in multiple cell types including microglia\",\n    \"Neuroinflammation is a well-replicated APOE4 phenotype with established mechanistic links to cholesterol dysregulation\"\n  ],\n  \"dissent_points\": [\n    \"Theorist proposes cholesterol synthesis dysregulation as primary pathology while skeptic argues elevated synthesis may be compensatory rather than harmful, fundamentally affecting therapeutic strategy\"\n  ],\n  \"debate_summary\": \"The debate identified microglial cholesterol-mediated neuroinflammation (via impaired ABCA1/ABCG1 efflux priming NLRP3 inflammasome) as the highest-impact, most mechanistically coherent hypothesis given established APOE4 phenotypes. The SREBP2 dysregulation model remains plausible but mechanistically contested, while the compensatory synthesis model challenges whether lipid binding deficits are pathogenic at all. Resolution requires distinguishing primary from secondary inflammatory markers in APOE4 carriers.\"\n}",
      "tokens_used": "917"
    }